Boulay Gaylor, Awad Mary E, Riggi Nicolo, Archer Tenley C, Iyer Sowmya, Boonseng Wannaporn E, Rossetti Nikki E, Naigles Beverly, Rengarajan Shruthi, Volorio Angela, Kim James C, Mesirov Jill P, Tamayo Pablo, Pomeroy Scott L, Aryee Martin J, Rivera Miguel N
Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Cancer Discov. 2017 Mar;7(3):288-301. doi: 10.1158/2159-8290.CD-16-0844. Epub 2017 Feb 17.
Medulloblastoma is the most frequent malignant pediatric brain tumor and is divided into at least four subgroups known as WNT, SHH, Group 3, and Group 4. Here, we characterized gene regulation mechanisms in the most aggressive subtype, Group 3 tumors, through genome-wide chromatin and expression profiling. Our results show that most active distal sites in these tumors are occupied by the transcription factor OTX2. Highly active OTX2-bound enhancers are often arranged as clusters of adjacent peaks and are also bound by the transcription factor NEUROD1. These sites are responsive to and knockdown and could also be generated upon ectopic expression in primary cells, showing that OTX2 cooperates with NEUROD1 and plays a major role in maintaining and possibly establishing regulatory elements as a pioneer factor. Among OTX2 target genes, we identified the kinase NEK2, whose knockdown and pharmacologic inhibition decreased cell viability. Our studies thus show that OTX2 controls the regulatory landscape of Group 3 medulloblastoma through cooperative activity at enhancer elements and contributes to the expression of critical target genes. The gene regulation mechanisms that drive medulloblastoma are not well understood. Using chromatin profiling, we find that the transcription factor OTX2 acts as a pioneer factor and, in cooperation with NEUROD1, controls the Group 3 medulloblastoma active enhancer landscape. OTX2 itself or its target genes, including the mitotic kinase NEK2, represent attractive targets for future therapies. .
髓母细胞瘤是最常见的儿童恶性脑肿瘤,至少分为四个亚组,即WNT、SHH、3组和4组。在此,我们通过全基因组染色质和表达谱分析,对最具侵袭性的亚组3组肿瘤中的基因调控机制进行了表征。我们的结果表明,这些肿瘤中大多数活跃的远端位点被转录因子OTX2占据。高度活跃的OTX2结合增强子通常排列为相邻峰的簇,并且也被转录因子NEUROD1结合。这些位点对OTX2和NEUROD1的敲低有反应,并且在原代细胞中异位表达OTX2时也可以产生,表明OTX2与NEUROD1协同作用,并作为先驱因子在维持和可能建立调控元件中起主要作用。在OTX2靶基因中,我们鉴定出激酶NEK2,其敲低和药理抑制降低了细胞活力。因此,我们的研究表明,OTX2通过在增强子元件处的协同活性控制3组髓母细胞瘤的调控格局,并有助于关键靶基因的表达。驱动髓母细胞瘤的基因调控机制尚未完全了解。通过染色质分析,我们发现转录因子OTX2作为先驱因子,并与NEUROD1协同作用,控制3组髓母细胞瘤的活跃增强子格局。OTX2本身或其靶基因,包括有丝分裂激酶NEK2,是未来治疗的有吸引力的靶点。